Lilly to acquire US radiopharmaceutical company POINT for $1.4bn
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
Sanofi, Janssen partner on potential E. coli pathogenic vaccine
04 Oct 23According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…
Baxter completes $4.5bn sale of BioPharma Solutions business
03 Oct 23Baxter’s BioPharma Solutions business will be renamed Simtra BioPharma Solutions (Simtra), which will continue to same solutions and…
American pharma company Viatris to sell certain businesses for $3.4bn
03 Oct 23The drugmaker has received offer for its OTC business, and has agreed to divest its women's healthcare business,…
Novo Nordisk’s Rivfloza secures FDA nod for adults, children with PH1
03 Oct 23The approval was supported by the positive findings from the Phase 2 PHYOX 2 clinical trial and interim…
UK’s MHRA approves Jemperli with chemotherapy in endometrial cancer treatment
03 Oct 23GSK’s Jemperli plus chemotherapy is now approved for patients with a tumour abnormality called mismatch repair deficient /…
Clade Therapeutics buys cell therapy company Gadeta
03 Oct 23The acquisition equips Clade with preclinical cell therapy programmes, a g/d TCR discovery engine, and cell enhancement technologies…
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
03 Oct 23Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule
IAMA Therapeutics Announces Multi-Phase, Strategic Provider Agreement with Evotec
03 Oct 23The agreement expands the companies' existing relationship, which entails collaborating on IND-enabling preclinical studies for IAMA-6
SGC, HitGen collaborate on DEL technology for drug discovery
29 Sep 23HitGen will leverage its DNA-encoded library (DEL) technology platform for the collaboration, specifically the OpenDEL solution, a self-service…